Apogenix secures funds to advance CD95L inhibitor
This article was originally published in Scrip
Executive Summary
Apogenix, a Heidelberg-based biopharmaceutical spinout from the German Cancer Research Center (DKFZ), has secured nearly €10 million to further advance APG101 its first-in-class, soluble human protein combining the extracellular domain of the CD95 receptor and the Fc portion of IgG. APG101 is the most advanced inhibitor of the CD95 ligand (CD95L) in clinical development.